ClinicalTrials.gg
Sign In
RecruitingNCT02663362MRS VALIDATIONUpdated Mar 30, 2026

Development and Validation of Multi-nuclear Magnetic Resonance Imaging and Spectroscopy for Whole Body Human Applications

An observational study in Human Body Composition and Human Body Function, sponsored by AdventHealth Translational Research Institute. Recruiting at 1 site in United States. Open to participants aged 12 Years to 89 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-30.

Sponsored by AdventHealth Translational Research Institute · Observational

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
250
Ages
12 Years to 89 Years
Sex
All
01

Study summary

The purpose of this study is to develop and refine the techniques for using magnetic resonance imaging and magnetic resonance spectroscopy to understand the composition and function of the human body

02

Conditions studied

  • Human Body Composition
  • Human Body Function

Keywords

  • magnetic resonance imaging
  • magnetic resonance spectroscopy
03

In context

Lead sponsor

AdventHealth Translational Research Institute is the lead sponsor of 57 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

A healthy individual, who is willing and able to undergo MR imaging and spectroscopy for up to two hours at a time

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female
  • Age 12 - 89
  • Healthy (self assessed)
  • Weight under 350lbs
  • Able to walk 50 yards without stopping
  • Able to travel to hospital for study visits
  • Able to follow a 3-step command
  • Able to remain in Magnetic Resonance (MR) scanner for up to 2 hours

Exclusion criteria

Exclusion Criteria:

  • Have internal metal medical devices, including cardiac pacemakers, aortic or cerebral aneurysm clips, artificial heart valves, ferromagnetic implants, shrapnel, wire sutures, joint replacements, bone or joint pins/rods/screws, metal fragments in your eye, or non-removable jewelry such as rings.
  • Are unwilling or unable to complete the imaging procedures for the duration of the MRI scan due to claustrophobia or other reason.
  • Serious mental illness that might preclude subject's ability to comply with study treatment
  • of less than 1 year
  • Are pregnant or plan on becoming pregnant in the next 8 weeks.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
250 participants (estimated)
Patient registry
No

Interventions

  • OtherTo evaluate the reproducibility of acquiring multi-nuclear data on a new 3T Philips Magnet

    Outside standard MR instrumentation there will be no interventions.

06

What researchers measure

Primary outcomes

  1. Whole body fat quantification

    Time frame: 1 hour

Secondary outcomes

  1. Fat Microstructure

    A high resolution image of the structure of fat tissue.

    Time frame: 1 hour

Other outcomes

  1. Flow high resolution imaging

    Image of the movement of fluids in the area being imaged.

    Time frame: 1 hour

  2. Intramyocellular fat quantification

    Use to determine the amount and types of fat inside muscle and liver.

    Time frame: 45 minutes

  3. Intrahepatic fat quantification

    A measure of the amount of fat in the liver.

    Time frame: 45 minutes

07

Study locations

1 of 1 sites recruiting
  • Translational Research Institute for Metabolism and Diabetes
    Orlando, Florida 32804, United States
    Recruiting
    • Recruitment Manager · Contacttri@flhosp.org · 407-303-7100
    • Heather Cornnell, PhD · Principal investigator
08

References and documents

Publications

  • Tyler DJ, Hudsmith LE, Clarke K, Neubauer S, Robson MD. A comparison of cardiac (31)P MRS at 1.5 and 3 T. NMR Biomed. 2008 Oct;21(8):793-8. doi: 10.1002/nbm.1255. PubMed 18512846 ↗
  • Muller HP, Raudies F, Unrath A, Neumann H, Ludolph AC, Kassubek J. Quantification of human body fat tissue percentage by MRI. NMR Biomed. 2011 Jan;24(1):17-24. doi: 10.1002/nbm.1549. PubMed 20672389 ↗
  • Price RR, Allison J, Massoth RJ, Clarke GD, Drost DJ; NMR Task Group #8. Practical aspects of functional MRI (NMR Task Group #8). Med Phys. 2002 Aug;29(8):1892-912. doi: 10.1118/1.1494990. PubMed 12201436 ↗
  • Noseworthy MD, Bulte DP, Alfonsi J. BOLD magnetic resonance imaging of skeletal muscle. Semin Musculoskelet Radiol. 2003 Dec;7(4):307-15. doi: 10.1055/s-2004-815678. PubMed 14735429 ↗
  • Lebon V, Dufour S, Petersen KF, Ren J, Jucker BM, Slezak LA, Cline GW, Rothman DL, Shulman GI. Effect of triiodothyronine on mitochondrial energy coupling in human skeletal muscle. J Clin Invest. 2001 Sep;108(5):733-7. doi: 10.1172/JCI11775. PubMed 11544279 ↗
  • Roser W, Beckmann N, Wiesmann U, Seelig J. Absolute quantification of the hepatic glycogen content in a patient with glycogen storage disease by 13C magnetic resonance spectroscopy. Magn Reson Imaging. 1996;14(10):1217-20. doi: 10.1016/s0730-725x(96)00243-3. PubMed 9065913 ↗
  • Beckmann N, Fried R, Turkalj I, Seelig J, Keller U, Stalder G. Noninvasive observation of hepatic glycogen formation in man by 13C MRS after oral and intravenous glucose administration. Magn Reson Med. 1993 May;29(5):583-90. doi: 10.1002/mrm.1910290502. PubMed 8505893 ↗
  • van der Meer RW, Doornbos J, Kozerke S, Schar M, Bax JJ, Hammer S, Smit JW, Romijn JA, Diamant M, Rijzewijk LJ, de Roos A, Lamb HJ. Metabolic imaging of myocardial triglyceride content: reproducibility of 1H MR spectroscopy with respiratory navigator gating in volunteers. Radiology. 2007 Oct;245(1):251-7. doi: 10.1148/radiol.2451061904. PubMed 17885193 ↗
  • Schar M, Kozerke S, Boesiger P. Navigator gating and volume tracking for double-triggered cardiac proton spectroscopy at 3 Tesla. Magn Reson Med. 2004 Jun;51(6):1091-5. doi: 10.1002/mrm.20123. PubMed 15170826 ↗
  • Hudsmith LE, Tyler DJ, Emmanuel Y, Petersen SE, Francis JM, Watkins H, Clarke K, Robson MD, Neubauer S. (31)P cardiac magnetic resonance spectroscopy during leg exercise at 3 Tesla. Int J Cardiovasc Imaging. 2009 Dec;25(8):819-26. doi: 10.1007/s10554-009-9492-8. Epub 2009 Aug 21. PubMed 19697152 ↗
  • Shen W, Mao X, Wang Z, Punyanitya M, Heymsfield SB, Shungu DC. Measurement of intramyocellular lipid levels with 2-D magnetic resonance spectroscopic imaging at 1.5 T. Acta Diabetol. 2003 Oct;40 Suppl 1(Suppl 1):S51-4. doi: 10.1007/s00592-003-0026-x. PubMed 14618433 ↗
  • Shen W, Mao X, Wolper C, Heshka S, Dashnaw S, Hirsch J, Heymsfield SB, Shungu DC. Reproducibility of single- and multi-voxel 1H MRS measurements of intramyocellular lipid in overweight and lean subjects under conditions of controlled dietary calorie and fat intake. NMR Biomed. 2008 Jun;21(5):498-506. doi: 10.1002/nbm.1218. PubMed 17955571 ↗
  • Larson-Meyer DE, Newcomer BR, Hunter GR. Influence of endurance running and recovery diet on intramyocellular lipid content in women: a 1H NMR study. Am J Physiol Endocrinol Metab. 2002 Jan;282(1):E95-E106. doi: 10.1152/ajpendo.2002.282.1.E95. PubMed 11739089 ↗
  • Larson-Meyer DE, Smith SR, Heilbronn LK, Kelley DE, Ravussin E, Newcomer BR; Look AHEAD Adipose Research Group. Muscle-associated triglyceride measured by computed tomography and magnetic resonance spectroscopy. Obesity (Silver Spring). 2006 Jan;14(1):73-87. doi: 10.1038/oby.2006.10. PubMed 16493125 ↗
  • Positano V, Gastaldelli A, Sironi AM, Santarelli MF, Lombardi M, Landini L. An accurate and robust method for unsupervised assessment of abdominal fat by MRI. J Magn Reson Imaging. 2004 Oct;20(4):684-9. doi: 10.1002/jmri.20167. PubMed 15390229 ↗
  • Smith SR, Lovejoy JC, Greenway F, Ryan D, deJonge L, de la Bretonne J, Volafova J, Bray GA. Contributions of total body fat, abdominal subcutaneous adipose tissue compartments, and visceral adipose tissue to the metabolic complications of obesity. Metabolism. 2001 Apr;50(4):425-35. doi: 10.1053/meta.2001.21693. PubMed 11288037 ↗
  • Larson-Meyer DE, Newcomer BR, Hunter GR, Joanisse DR, Weinsier RL, Bamman MM. Relation between in vivo and in vitro measurements of skeletal muscle oxidative metabolism. Muscle Nerve. 2001 Dec;24(12):1665-76. doi: 10.1002/mus.1202. PubMed 11745976 ↗
  • Larson-Meyer DE, Newcomer BR, Hunter GR, Hetherington HP, Weinsier RL. 31P MRS measurement of mitochondrial function in skeletal muscle: reliability, force-level sensitivity and relation to whole body maximal oxygen uptake. NMR Biomed. 2000 Jan;13(1):14-27. doi: 10.1002/(sici)1099-1492(200002)13:13.0.co;2-0. PubMed 10668050 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2012, a primary completion of Jun 2026 and a completion of Jan 2027. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2016
First posted
Jan 26, 2016
Start
Feb 2012
Primary completionEst.
Jun 2026
CompletionEst.
Jan 2027
Last update
Mar 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02663362
Lead sponsor
AdventHealth Translational Research Institute
Responsible party
Sponsor
First posted
Jan 26, 2016
Start date
Feb 2012
Primary completion
Jun 2026 (estimated)
Completion
Jan 2027 (estimated)
Last update
Mar 30, 2026

Study contacts

Recruitment Department
Contact
tri@flhosp.org
407-303-7100
Heather Cornnell, PhD
principal investigator · Translational Research Institute for Metabolism and Diabetes

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

AdventHealth Translational Research Institute

Start the discussion